Robeco Institutional Asset Management B.V. boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 29.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,368 shares of the medical equipment provider’s stock after purchasing an additional 3,304 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Lantheus were worth $1,206,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in LNTH. Vanguard Group Inc. increased its stake in Lantheus by 4.4% in the 3rd quarter. Vanguard Group Inc. now owns 7,765,120 shares of the medical equipment provider’s stock worth $546,121,000 after acquiring an additional 326,396 shares during the last quarter. Alliancebernstein L.P. increased its position in Lantheus by 18.1% during the 4th quarter. Alliancebernstein L.P. now owns 3,193,302 shares of the medical equipment provider’s stock valued at $162,731,000 after purchasing an additional 489,203 shares during the period. State Street Corp increased its position in Lantheus by 0.3% during the 2nd quarter. State Street Corp now owns 2,393,559 shares of the medical equipment provider’s stock valued at $158,047,000 after purchasing an additional 7,307 shares during the period. Hood River Capital Management LLC increased its position in Lantheus by 4.0% during the 1st quarter. Hood River Capital Management LLC now owns 1,633,626 shares of the medical equipment provider’s stock valued at $134,872,000 after purchasing an additional 62,827 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Lantheus by 369.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,454,887 shares of the medical equipment provider’s stock valued at $120,115,000 after buying an additional 1,144,793 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.
Insider Activity
In related news, CAO Andrea Sabens sold 1,752 shares of the business’s stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $90.87, for a total value of $159,204.24. Following the completion of the sale, the chief accounting officer now owns 59,767 shares of the company’s stock, valued at approximately $5,431,027.29. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, President Paul Blanchfield sold 408 shares of the business’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $66.10, for a total value of $26,968.80. Following the completion of the sale, the president now owns 90,067 shares of the company’s stock, valued at approximately $5,953,428.70. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Andrea Sabens sold 1,752 shares of the business’s stock in a transaction on Wednesday, July 19th. The stock was sold at an average price of $90.87, for a total transaction of $159,204.24. Following the completion of the sale, the chief accounting officer now directly owns 59,767 shares of the company’s stock, valued at approximately $5,431,027.29. The disclosure for this sale can be found here. Insiders sold a total of 22,161 shares of company stock valued at $1,542,833 in the last three months. 1.50% of the stock is currently owned by corporate insiders.
Lantheus Price Performance
Lantheus (NASDAQ:LNTH – Get Free Report) last posted its earnings results on Thursday, August 3rd. The medical equipment provider reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.17. The firm had revenue of $321.70 million during the quarter, compared to analyst estimates of $306.48 million. Lantheus had a net margin of 2.97% and a return on equity of 67.18%. Equities research analysts forecast that Lantheus Holdings, Inc. will post 5.18 EPS for the current year.
Wall Street Analyst Weigh In
LNTH has been the subject of a number of recent analyst reports. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, September 29th. TheStreet upgraded shares of Lantheus from a “c” rating to a “b-” rating in a research note on Wednesday, August 9th. B. Riley restated a “buy” rating and set a $113.00 price objective on shares of Lantheus in a research note on Tuesday, October 3rd. Truist Financial restated a “buy” rating and set a $110.00 price objective on shares of Lantheus in a research note on Wednesday, October 4th. Finally, Mizuho restated a “buy” rating and set a $125.00 price objective on shares of Lantheus in a research note on Wednesday, October 4th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $120.83.
Check Out Our Latest Stock Report on LNTH
Lantheus Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.
Featured Articles
- Five stocks we like better than Lantheus
- How to Use the MarketBeat Dividend Calculator
- What BlackRock’s Earnings Tell You About The Stock Market Tide
- Video Game Stocks: How to Invest in Gaming
- Sociedad Quimica y Minera de Chile Well Positioned Lithium Stock
- The Dividend Kings With Highest Yield
- SMART Global Holdings Now Positioned for Upside
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
